Skip to content

Study · Randomized controlled trial · n = 21 · 2010

5 results

Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study.

Fazeli PK, Lawson EA, Prabhakaran R, Miller KK, Donoho DA, Clemmons DR, Herzog DB, Misra M, Klibanski A

The Journal of clinical endocrinology and metabolism28 Jul 2010Cited by 76 (Europe PMC)

PMID20668047 (opens in a new tab)PMCIDPMC2968733 (opens in a new tab)DOI10.1210/jc.2010-0493 (opens in a new tab)PepBankPUB-20668047
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with anorexia nervosa, IGF-I after treatment did not differ between rhGH and placebo (124 versus 85.5 ng/ml; P = 0.3).

    In plain wordsIn women with anorexia nervosa, IGF-I after treatment did not differ between rhGH and placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeIGF-I after treatment
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    mean maximum daily dose 1.4 ± 0.12 mg/d · 12 weeksAs given in this study (human).

    Measurements

    IGF-I
    124 ng/ml
    rhGH median at 12 weeks, interquartile range 94.5 to 170.3
    IGF-I
    85.5 ng/ml
    placebo median at 12 weeks, interquartile range 62 to 139

    Source sentences

    Summary
    IGF-I levels did not differ between the groups at baseline or after treatment (median after 12 wk-rhGH, 124 ng/ml, interquartile range, 94.5, 170.3; vs. placebo, 85.5 ng/ml, interquartile range, 62, 139; P = 0.3).
    3 context sentences
    Summary · context
    We conducted a randomized, placebo-controlled study in a Clinical Research Center.
    Summary · context
    We studied 21 women with AN, 10 (mean age, 28 ± 2.1 yr) treated with rhGH and 11 (mean age, 29.2 ± 2.6 yr) treated with placebo.
    Summary · context
    rhGH (mean maximum daily dose, 1.4 ± 0.12 mg/d) or placebo was administered to patients for 12 wk.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with anorexia nervosa, changes in glucose, insulin, free fatty acids, and bone markers did not differ between rhGH and placebo.

    In plain wordsIn women with anorexia nervosa, changes in glucose, insulin, free fatty acids, and bone markers did not differ between rhGH and placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeGlucose, insulin, free fatty acid and bone marker changes
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Metabolic pathways and metabolomics · Whole body
    Studied dose
    mean maximum daily dose 1.4 ± 0.12 mg/d · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Similarly, changes in glucose, insulin, free fatty acids, and bone markers did not differ between the groups.
    3 context sentences
    Summary · context
    We conducted a randomized, placebo-controlled study in a Clinical Research Center.
    Summary · context
    We studied 21 women with AN, 10 (mean age, 28 ± 2.1 yr) treated with rhGH and 11 (mean age, 29.2 ± 2.6 yr) treated with placebo.
    Summary · context
    rhGH (mean maximum daily dose, 1.4 ± 0.12 mg/d) or placebo was administered to patients for 12 wk.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with anorexia nervosa, rhGH reduced total fat mass compared with placebo.

    In plain wordsIn women with anorexia nervosa, rhGH reduced total fat mass compared with placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseTotal fat mass
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    mean maximum daily dose 1.4 ± 0.12 mg/d · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Total fat mass and percentage fat mass (rhGH, -2.5 ± 0.6%, vs. placebo, 2.2 ± 1.1%; P = 0.004) decreased significantly in the rhGH group compared to placebo despite comparable weight.
    3 context sentences
    Summary · context
    We conducted a randomized, placebo-controlled study in a Clinical Research Center.
    Summary · context
    We studied 21 women with AN, 10 (mean age, 28 ± 2.1 yr) treated with rhGH and 11 (mean age, 29.2 ± 2.6 yr) treated with placebo.
    Summary · context
    rhGH (mean maximum daily dose, 1.4 ± 0.12 mg/d) or placebo was administered to patients for 12 wk.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with anorexia nervosa, percentage fat mass changed by -2.5 ± 0.6% with rhGH versus 2.2 ± 1.1% with placebo (P = 0.004).

    In plain wordsIn women with anorexia nervosa, rhGH reduced percentage fat mass compared with placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreasePercentage fat mass
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    mean maximum daily dose 1.4 ± 0.12 mg/d · 12 weeksAs given in this study (human).

    Measurements

    Percentage fat mass change
    −2.5%
    rhGH
    Percentage fat mass change
    2.2%
    placebo

    Source sentences

    Summary
    Total fat mass and percentage fat mass (rhGH, -2.5 ± 0.6%, vs. placebo, 2.2 ± 1.1%; P = 0.004) decreased significantly in the rhGH group compared to placebo despite comparable weight.
    3 context sentences
    Summary · context
    We conducted a randomized, placebo-controlled study in a Clinical Research Center.
    Summary · context
    We studied 21 women with AN, 10 (mean age, 28 ± 2.1 yr) treated with rhGH and 11 (mean age, 29.2 ± 2.6 yr) treated with placebo.
    Summary · context
    rhGH (mean maximum daily dose, 1.4 ± 0.12 mg/d) or placebo was administered to patients for 12 wk.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with anorexia nervosa, weight was comparable between rhGH and placebo groups.

    In plain wordsIn women with anorexia nervosa, weight was comparable between rhGH and placebo groups.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeWeight
    Study

    n = 21

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    mean maximum daily dose 1.4 ± 0.12 mg/d · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Total fat mass and percentage fat mass (rhGH, -2.5 ± 0.6%, vs. placebo, 2.2 ± 1.1%; P = 0.004) decreased significantly in the rhGH group compared to placebo despite comparable weight.
    3 context sentences
    Summary · context
    We conducted a randomized, placebo-controlled study in a Clinical Research Center.
    Summary · context
    We studied 21 women with AN, 10 (mean age, 28 ± 2.1 yr) treated with rhGH and 11 (mean age, 29.2 ± 2.6 yr) treated with placebo.
    Summary · context
    rhGH (mean maximum daily dose, 1.4 ± 0.12 mg/d) or placebo was administered to patients for 12 wk.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.